28 completed, 20 recruiting, 16 not yet recruiting, 10 unknown. 24 Phase 1, 24 Phase 2, 8 Early Phase 1, 8 Phase 3, 3 Not applicable.
Follow Anemia, Hemolytic, Autoimmune: new trials by email Literature Review of Anemia, Hemolytic, Autoimmune trials Research Report on Anemia, Hemolytic, Autoimmune
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Research on YTS109 Cell in Patients With Recurrent/Refractory Autoimmune Hemolytic Anemia YTS109 cell - Autoimmune Hemolytic Anemia | Phase 1 | Not yet recruiting | China Immunotech (Beijing) Biotechnology Co., Ltd. | 13 | 2026-11-18 | 2026-10-22 |
| Phase 1 Study of F182112 in Relapsed/Refractory Autoimmune Hemolytic Anemia F182112 single-agent - Autoimmune Hemolytic Anemia | Phase 1 | Not yet recruiting | Institute of Hematology & Blood Diseases Hospital, China | 12 | 2026-10-10 | 2026-09-11 |
| META 10-19 in Patients With Relapsed/Refractory Autoimmune Hemolytic Anemia Metabolically Armed Autologous CD19 CAR T-Cell therapy - Autoimmune Hemolytic Anemia (AIHA) | Early Phase 1 | Not yet recruiting | Institute of Hematology & Blood Diseases Hospital, China | 18 | 2026-09-20 | 2026-09-21 |
| Study of Zola-cel (BMS-986353), in Participants With Autoimmune Cytopenia (Breakfree-AiCE) BMS-986353, Fludarabine Phosphate, Cyclophosphamide - Chronic Immune Thrombocytopenia, Autoimmune Hemolytic Anemia | Phase 2 | Not yet recruiting | Juno Therapeutics, Inc., a Bristol-Myers Squibb Company | 52 | 2026-08-31 | 2026-07-09 |
| HY001N for Patients With Autoimmune Hemolytic Anemia After Failure ≥3 Lines of Therapy. HY001N Cell Injection - Autoimmune Hemolytic Anemia (AIHA) | Phase 1 | Recruiting | Juventas Cell Therapy Ltd. | 9 | 2026-07-02 | 2026-08-05 |
| IASO206 in Patients With Relapsed/Refractory Autoimmune Hemolytic Anemia IASO206 injection - Autoimmune Hemolytic Anemia, Relapsed/Refractory | Phase 1 | Not yet recruiting | Institute of Hematology & Blood Diseases Hospital, China | 18 | 2026-06-15 | 2026-05-13 |
| CD20 Monoclonal Antibody Combined With BTK Inhibitor for the Treatment of Refractory Immune-related Cytopenia Anti-CD20 monoclonal antibody and the BTK inhibitor - Anti-CD20 Monoclonal Antibody, BTK Inhibitors | Phase 1 | Not yet recruiting | Qi deng | 30 | 2026-06-01 | 2026-05-22 |
| Evaluation of Safety, Pharmacokinetics and Pharmacodynamics of Arnovie101, an mRNA-LNP-Based In Vivo CAR-T Therapy, for the Treatment of B Cell-Mediated Autoimmune Diseases (SLE and AIHA) Arnovie101 Infusion Intravenous - Systemic Lupus Erythematosus, Autoimmune Hemolytic Anemia (AIHA) | Early Phase 1 | Recruiting | Circunited BioPharma (Shenzhen) Co., Ltd. | 5 | 2026-04-07 | 2026-06-05 |
| A Multicenter, Prospective, Randomized Controlled Study Comparing Glucocorticoid Combined With Sirolimus With Monotherapy of Glucocorticoid in the Treatment of Newly Diagnosed Mild Autoimmune Hemolytic Anemia Glucocorticoids - Autoimmune Hemolytic Anemia (AIHA) | Not applicable | Not yet recruiting | Chen Miao | 216 | 2026-04-01 | 2026-04-08 |
| Orelabrutinib in the Treatment of Relapsed/Refractory AIHA Orelabrutinib-50, Orelabrutinib-100, Orelabrutinib-150 - Autoimmune Hemolytic Anemia (AIHA) | Phase 2 | Recruiting | Peking Union Medical College Hospital | 50 | 2026-03-01 | 2026-06-16 |
| UCAR-T Targeting CD19/BCMA in Subjects With Autoantibody-Mediated Autoimmune Benign Hematological Diseases CART Infusion - Autoimmune Hemolytic Anemia, Primary Immune Thrombocytopenic Purpura | Early Phase 1 | Recruiting | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | 27 | 2026-02-03 | 2026-03-02 |
| Inaticabtagene Autoleucel Injection in the Treatment of Autoimmune Hemolytic Anemia After Three or More Lines of Therapy Inaticabtagene Autoleucel Injection - AIHA - Cold Autoimmune Hemolytic Anemia | Phase 1 | Not yet recruiting | Juventas Cell Therapy Ltd. | 12 | 2025-12-27 | 2025-09-22 |
| A Study of YTS109 Cell in Subjects With Relapsed/Refractory Autoimmune Hemolytic Anemia YTS109 cell - Autoimmune Hemolytic Anemia | Phase 1 | Not yet recruiting | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | 13 | 2025-12-25 | 2025-12-17 |
| A Study of CM336 in Patients With Relapsed or Refractory Autoimmune Cytopenia CM336 Injection - Autoimmune Cytopenia, Immune Thrombocytopenia (ITP) | Phase 1 / Phase 2 | Recruiting | Keymed Biosciences Co.Ltd | 158 | 2025-11-18 | 2025-12-17 |
| Autologous CD19/BCMA Dual-Target CAR-T for Relapsed/Refractory Autoimmune Diseases Autologous CD19-BCMA Dual-Target CAR T-Cell Therapy - Relapsed/Refractory Systemic Lupus Erythematosus, Relapsed/Refractory Systemic Sclerosis | Phase 1 | Withdrawn | Beijing Boren Hospital | 2025-11-06 | 2026-10-15 | |
| Brain Cognitive Network Abnormalities in Anemia Patients Using fNIRS Aplastic Anemia, Myelodysplastic Syndromes | Recruiting | Institute of Hematology & Blood Diseases Hospital, China | 323 | 2025-10-11 | 2026-09-18 | |
| A Clinical Study Evaluating the Safety and Efficacy of GT801 Injection in Adult Patients With Relapsed/Refractory CD19-positive B-cell Hematologic Malignancies and Autoimmune Hemolytic Anemia GT801 Injection - B-cell Acute Lymphoblastic Leukemia (B-ALL), Chronic Lymphocytic Leukemia (CLL) | Early Phase 1 | Recruiting | Grit Biotechnology | 28 | 2025-09-26 | 2026-07-20 |
| A Single-arm Phase 2 Prospective Clinical Study of Enatumab in the Treatment of Relapsed/Refractory Warm Antibody Autoimmune Hemolytic Anemia enatumab - Autoimmune Hemolytic Anemia | Phase 2 | Not yet recruiting | Bing Han | 3 | 2025-09-18 | 2025-09-24 |
| A Single-arm Phase 2 Prospective Clinical Study of Linprixel in the Treatment of Relapsed/Refractory Autoimmune Hemolytic Anemia Parsaclisib - Autoimmune Hemolytic Anemia | Not yet recruiting | Peking Union Medical College Hospital | 22 | 2025-09-01 | 2025-09-02 | |
| A Study to Investigate the Efficacy, Safety, and Pharmacokinetics of Oral Rilzabrutinib Compared With Placebo in Participants 18 Years of Age and Older With Warm Autoimmune Hemolytic Anemia rilzabrutinib, placebo - Autoimmune Haemolytic Anaemia | Phase 3 | Recruiting | Sanofi | 90 | 2025-08-18 | 2026-10-20 |
Showing 20 of 83. Sign in to see all of them.
Purpura, Thrombocytopenic, Idiopathic (18) · Evans Syndrome (9) · Lupus Erythematosus, Systemic (8) · Hemolysis (6) · Anemia (5) · Anemia, Hemolytic (4) · Autoimmune Diseases (4) · Hematologic Diseases (4) · Myelodysplastic Syndromes (4) · Recurrence (4) · Anemia, Aplastic (3) · Arthritis, Rheumatoid (3) · Cytopenia (3) · Leukemia, Lymphocytic, Chronic, B-Cell (3)
Hemic and Lymphatic Diseases (83) · Immune System Diseases (81) · Anemia, Hemolytic (79) · Autoimmune Diseases (79) · Hematologic Diseases (79) · Anemia (78) · Pathological Conditions, Signs and Symptoms (30) · Pathologic Processes (29) · Blood Platelet Disorders (20) · Hemorrhagic Disorders (20) · Blood Coagulation Disorders (19) · Hemorrhage (18) · Purpura (18) · Signs and Symptoms (18) · Skin Manifestations (18)
Rituximab (7) · Blood Specimen Collection (4) · sutimlimab (4) · Cyclophosphamide (3) · Bortezomib (2) · Filgrastim (2) · Prednisone (2) · ibrutinib (2) · iptacopan (2) · parsaclisib (2) · Alemtuzumab (1) · Antilymphocyte Serum (1) · Bendamustine Hydrochloride (1) · Crisis Intervention (1) · Cyclosporine (1)
Institute of Hematology & Blood Diseases Hospital, China (15) · Bioverativ, a Sanofi company (5) · University Hospital, Bordeaux (5) · Assiut University (4) · Peking Union Medical College Hospital (4) · Centre Hospitalier Universitaire Dijon (3) · Union Hospital, Tongji Medical College, Huazhong University of Science and Technology (3) · Bing Han (2) · China Immunotech (Beijing) Biotechnology Co., Ltd. (2) · Gruppo Italiano Malattie EMatologiche dell'Adulto (2) · Juventas Cell Therapy Ltd. (2) · Sanofi (2) · University Hospital, Toulouse (2) · Zhejiang University (2) · Alpine Immune Sciences Inc, A Subsidiary of Vertex (1)
China (32) · United States (18) · Italy (14) · France (12) · Germany (11) · Austria (9) · United Kingdom (9) · Norway (8) · Netherlands (7) · Spain (7) · Japan (6) · Australia (5) · Canada (4) · Denmark (4) · Belgium (3)
Geir E Tjonnfjord, MD, PhD (2) · Jun Shi (2) · Sigbjorn Berentsen, MD, PhD (2) · Alexander Roeth, MD (1) · Alexey Danilov (1) · Arne Slungaard (1) · Bing Han (1) · Bing Hang, PhD (1) · David Gomez-Almaguer, MD (1) · David T. Teachey, MD (1) · Elling Ulvestad, MD, PhD (1) · Essam Abdel Monem El-beih, professor (1)
PMID 40308078, PMID 16041665, PMID 18644324, PMID 19055865, PMID 19105232, PMID 19208097, PMID 19819109, PMID 20634373, PMID 20841509, PMID 24034070, PMID 25271314, PMID 26504182, PMID 26696797, PMID 26696800, PMID 27716293, PMID 28533306, PMID 28926521, PMID 28980446, PMID 29268404, PMID 30291112, PMID 30408135, PMID 30559259, PMID 32611669, PMID 33826820, PMID 34778998, PMID 35687757, PMID 35999387, PMID 36403132, PMID 36647781, PMID 37246953, PMID 37459203, PMID 37534514, PMID 37534543, PMID 37680953, PMID 37846845, PMID 37967471, PMID 38013593, PMID 38029356, PMID 38085846, PMID 38170583, PMID 38227934, PMID 38249329, PMID 38505288, PMID 38995690, PMID 39095502, PMID 39435908, PMID 39486046, PMID 39874521, PMID 40353947, PMID 41366634
2017 (3), 2014 (2), 2019 (2), 2023 (2), 2009 (1), P30CA033572 (1)